Evidence map›Paper›PMID 10097144›Full record

Trial reportProceedings of the National Academy of Sciences of the United States of America1999

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

G D Demetri, C D Fletcher, E Mueller, P Sarraf, R Naujoks, N Campbell, B M Spiegelman, S Singer

Registry-linked trialOpen access · greenAbstract readCase ReportsClinical TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003058 (Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma), which is not on this map. Cited by 166 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 2 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00003058 phase2completednot on this map

Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma

TypeinterventionalSponsorDana-Farber Cancer InstituteRan1997 to 2000Enrolled85ConditionsSarcomaArmstroglitazone
3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 2 syntheses or guidelines pooled it, 490 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2000
    Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

G D DemetriDepartment of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
C D Fletcher
E Mueller
P Sarraf
R Naujoks
N Campbell
B M Spiegelman
S Singer
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHarvard University · USUniversity of California, San Diego · US

Funding

NOVEL BIOCHEMICAL DETERMINANTS FOR SOFT TISSUE SARCOMAR01CA075720 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI SINGER, SAMUEL I · 1998 to 1999
–
NCI NIH HHS R01 CA75720-01
6 · The paper itself

Abstract

Agonist ligands for the nuclear receptor peroxisome proliferator-activated receptor-gamma have been shown to induce terminal differentiation of normal preadipocytes and human liposarcoma cells in vitro. Because the differentiation status of liposarcoma is predictive of clinical outcomes, modulation of the differentiation status of a tumor may favorably impact clinical behavior. We have conducted a clinical trial for treatment of patients with advanced liposarcoma by using the peroxisome proliferator-activated receptor-gamma ligand troglitazone, in which extensive correlative laboratory studies of tumor differentiation were performed. We report here the results of three patients with intermediate to high-grade liposarcomas in whom troglitazone administration induced histologic and biochemical differentiation in vivo. Biopsies of tumors from each of these patients while on troglitazone demonstrated histologic evidence of extensive lipid accumulation by tumor cells and substantial increases in NMR-detectable tumor triglycerides compared with pretreatment biopsies. In addition, expression of several mRNA transcripts characteristic of differentiation in the adipocyte lineage was induced. There was also a marked reduction in immunohistochemical expression of Ki-67, a marker of cell proliferation. Together, these data indicate that terminal adipocytic differentiation was induced in these malignant tumors by troglitazone. These results indicate that lineage-appropriate differentiation can be induced pharmacologically in a human solid tumor.

Indexed as

ThiazolidinedionesAdultBiopsyCell DifferentiationChromansDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansLigandsLiposarcomaMaleMiddle AgedPhosphatidylcholinesReceptors, Cytoplasmic and NuclearThiazolesChromansDNA-Binding ProteinsLigandsPhosphatidylcholinesReceptors, Cytoplasmic and NuclearThiazolesThiazolidinedionesTranscription FactorsTriglyceridesTroglitazone

Identifiers

PMID10097144
PMCPMC22401
OpenAlexW2050352100

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.